Table 3 Event rates and adjusted hazard ratio (95% confidence interval, CI) for clinical endpoints using multivariable Cox regression analysis in 6454 type 2 diabetic patients stratified by use of aspirin for primary or secondary prevention of cardiovascular disease.
|  | Overall | Aspirin users | Non-aspirin users | Hazard ratio* (95% CI) | p-value†|
|---|---|---|---|---|---|
Primary prevention cohort: | n = 5,731 | n = 1,034 | n = 4,697 | - | - |
Primary composite endpoint | 398 (6.9%) | 138 (13.3%) | 260 (5.5%) | 2.07 (1.66 to 2.59) | < 0.001 |
Vascular death | 115 (2%) | 54 (5.2%) | 61 (1.3%) | 2.61 (1.70 to 4.01) | < 0.001 |
Non-fatal myocardial infarct | 67 (1.2%) | 27 (2.6%) | 40 (0.9%) | 2.05 (1.11 to 3.79) | 0.023 |
Non-fatal stroke | 251 (4.4%) | 71 (6.9%) | 180 (3.8%) | 1.52 (1.14 to 2.04)# | 0.005# |
Secondary prevention cohort: | n = 723 | n = 585 | n = 138 | - | - |
Primary composite endpoint | 145 (20.1%) | 116 (19.8%) | 29 (21%) | 0.91 (0.60 to 1.37)# | NS |
Vascular death | 69 (9.5%) | 55 (9.4%) | 14 (10.1%) | 0.92 (0.51 to 1.69)# | NS |
Non-fatal myocardial infarct | 23 (3.2%) | 20 (3.4%) | 3 (2.2%) | 1.42 (0.42 to 4.85)# | NS |
Non-fatal stroke | 73 (10.1%) | 55 (9.4%) | 18 (13%) | 0.71 (0.42 to 1.23)# | NS |
Complete cohort: | n = 6,454 | n = 1,619 | n = 4,835 | - | - |
Upper gastrointestinal bleeding | 138 (2.1%) | 70 (4.3%) | 68 (1.4%) | 2.19 (1.53 to 3.15) | < 0.001 |
Endoscopically-confirmed ulcer bleeding | 68 (1.1%) | 33 (2%) | 35 (0.7%) | 1.72 (1.02 to 2.91) | 0.043 |
Haemorrhagic stroke | 61 (0.9%) | 25 (1.5%) | 36 (0.7%) | 1.71 (1.00 to 2.95)# | 0.051# |